Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.

Miguel Ángel Climent Duran,Albert Font,Ignacio Duran,Javier Puente,Daniel Castellano,M Isabel Sáez,Maria Jose José Mendez Vidal,Carmen Santander,Jose Angel Arranz Arija,Aranzazu Gonzalez del Alba,Alfredo Sánchez Hernández,Emilio Esteban,Teresa Alonso-Gordoa,Pablo Maroto,Martin Lázaro Quintela,Javier Cassinello,B.P. Valderrama,María José Juan-Fita,Begoña Mellado

Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.

2020

Miguel Ángel Climent Duran
Albert Font
Ignacio Duran
Javier Puente
Daniel Castellano
M Isabel Sáez
Maria Jose José Mendez Vidal
Carmen Santander
Jose Angel Arranz Arija
Aranzazu Gonzalez del Alba
Alfredo Sánchez Hernández
Emilio Esteban
Teresa Alonso-Gordoa
Pablo Maroto
Martin Lázaro Quintela
Javier Cassinello
B.P. Valderrama
María José Juan-Fita
Begoña Mellado

95Background: Abiraterone acetate (AA) improves OS and rPFS in first line mCRPC patients (pts). After AA progression D is commonly used as standard second line therapy. However, the value of mainta...

Keywords:

Prostate cancer
Oncology
Pathology
Abiraterone acetate
Castration
Second-line therapy
Docetaxel
Internal medicine
disease progression
Medicine
first line
Phases of clinical research
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations